In Honor of Dr. Nichols, Mrs. Tricia Nichols and the Nichols Trust are sponsoring the 2nd annual Albert Nichols Symposium (ANS) organized by the Southern California Section of American Association for Clinical Chemistry (AACC).

The topic for the 2018 ANS is Precision Oncology. 

AGENDA (Tentative)

8:00am    .    .    .    .    .     Registration / Coffee
9:00am - 10:00am . . Morning Session I
10:00am - 10:15am  . . Break and Exhibits
10:15am - 12:15pm . . Morning Session II
12:15pm - 1:00pm . . Lunch and Exhibits
1:00pm - 3:00pm . . .Afternoon Session I
3:00pm - 3:30pm . . Break and Exhibits
3:30pm - 5:30pm . . .Afternoon Sessions II
5:30pm - 6:30pm  . . .Reception

 

PRESENTATIONS & SPEAKERS (Tentative)

 

From Precision Medicine to Novel Therapeutics in Lung Cancer:Role of MET RTK

Ravi Salgia, MD, PhD

City of Hope, Duarte, CA

Precision Oncology in Prostate Cancer:New Opportunities with Blood-based Diagnostics

Edwin Posadas, MD

Cedars-Sinai Medical Center, Los Angeles, CA

Updates in Therapy of Advanced Melanoma

April Salama, MD

Duke University Oncology Institute, Durham, NC

Clinical Use of Biomarkers in Breast Cancer

Yuri Fesko, MD

Quest Diagnostics, Secaucus, NJ

Practical Approaches For Stratifying NGS Assays in Precision Oncology

Helen Fernandez, PhD

Columbia University, NY

David vs Goliath: Balancing Use of Small and Large NGS Panels In Cancer Diagnostics and Germline Cancer Risk

Dan Jones, MD, PhD

Ohio State University, Columbus, OH

 

Additional speaker(s) to be determined

 

CONTINUING EDUCATION:  7 hours of CE and CME credits have been submitted for approval:

Target (Intended) Audience:

• Physicians 
• Laboratory Directors
• Laboratory Managers and Supervisors
• Clinical Laboratory Scientists/Medical Technologists
• Residents/Fellows

Learning Objectives:

1.      Develop an overview of the recent developments in lung, prostate, skin, breast any myeloid tumors.

2.      The learner will be able to describe the current biomarkers used in clinical practice for the diagnosis and management of various cancers.

3.      The learner will be able to describe recent methods used for in vitro diagnostic testing (both molecular and non molecular).

4.      The learner will be able to describe recent drug development and their clinical applications for cancers.

 

Parking: Complimentary Self-Parking

Hotel/Lodging: A limited number of rooms available at reduced rate for the symposium. Please call 1-800-Hiltons and ask for the ZSD discounted rate.

 

Register Now! 

PRESENTED BY

About Dr. Albert Nichols

Dr. Albert Nichols was an Assistant Professor at UCLA Harbor Medical Center before he started Nichols Institute for Endocrinology in Southern California in the early 1970s. His journey started in the early 1960s when he was a Fellow of Endocrinology at Mass General Hospital (Harvard University) in Boston. He and others had developed endocrinology tests using a new technology called radioimmunoassay (RIA) that allowed the measurement of small quantities of hormones and other biomarkers in patient samples. These hormone tests have revolutionized the practice of medicine. He soon realized that these new tests were not available to most clinicians and there was a delay for the tests to go from research to clinicians. Dr. Nichols started the laboratory called Nichols Institute initially for endocrine tests with the help from academic investigators. He later expanded the tests in various other clinical disciplines such as oncology, genetics, infectious disease, toxicology, immunology, etc. Though he left us at an early age of 67, his legacy as Quest Diagnostics Nichols Institute continues.